Sanofi Ventures logo

Sanofi Ventures

North America, Massachusetts, United States, Cambridge

Description

Sanofi Ventures operates as the dedicated corporate venture capital arm of Sanofi, a leading global healthcare company. Established to identify and invest in innovative life science companies, the firm strategically aligns its investments with Sanofi's core therapeutic areas and emerging healthcare needs. Its primary mission is to foster groundbreaking scientific advancements and technological solutions that have the potential to transform patient care and contribute to Sanofi's long-term growth objectives. Sanofi Ventures leverages Sanofi's extensive R&D capabilities, global network, and deep industry expertise to provide portfolio companies with more than just capital, offering strategic guidance and operational support.

The firm primarily targets early to growth-stage companies, typically participating in Series A, B, and C rounds. Their investment focus spans a broad spectrum of life science innovations, including novel therapeutics, digital health solutions, medical devices, and other healthcare technologies. Sanofi Ventures seeks companies that are developing disruptive technologies or platforms with strong scientific foundations and clear pathways to clinical and commercial success. They often co-invest with other prominent venture capital firms, demonstrating a collaborative approach to funding promising ventures within the highly competitive biotech and healthcare sectors.

Sanofi Ventures manages a substantial pool of capital, with over $500 million in assets under management, enabling significant investments across its portfolio. This financial capacity allows them to support companies through multiple funding rounds as they progress through development milestones. Their portfolio comprises over 50 companies, reflecting a diversified investment strategy across various disease areas and technological modalities. The firm's commitment extends beyond initial funding, as they actively work to build long-term partnerships, aiming to accelerate the development and commercialization of innovative solutions that address critical unmet medical needs globally.

Investor Profile

Sanofi Ventures has backed more than 96 startups, with 14 new investments in the last 12 months alone. The firm has led 24 rounds, about 25% of its total and boasts 22 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series A, Series C rounds (top funding stages).
  • Majority of deals are located in United States, Denmark, United Kingdom.
  • Strong thematic focus on Biotechnology, Health Care, Medical.
  • Led 5 rounds in the past year.
  • Typical check size: $5M – $15M.

Stage Focus

  • Series B (43%)
  • Series A (26%)
  • Series C (16%)
  • Seed (6%)
  • Series Unknown (4%)
  • Post Ipo Equity (2%)
  • Series D (2%)
  • Series E (1%)

Country Focus

  • United States (84%)
  • Denmark (4%)
  • United Kingdom (3%)
  • France (2%)
  • Australia (2%)
  • Israel (1%)
  • The Netherlands (1%)
  • Switzerland (1%)
  • Spain (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
  • Life Science
  • Biopharma
  • Wellness
  • Medical Device
  • Genetics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Sanofi Ventures frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 8
Abingworth
Europe, England, United Kingdom, London
Co-Investments: 7
Novartis Venture Fund
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 9
Alexandria Venture Investments
North America, California, United States, Pasadena
Co-Investments: 8
New Enterprise Associates
North America, California, United States, Menlo Park
Co-Investments: 11
Atlas Venture
North America, Massachusetts, United States, Cambridge
Co-Investments: 7
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 12
Novo Holdings
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 7
OUP (Osage University Partners)
North America, Pennsylvania, United States, Bala Cynwyd
Co-Investments: 9
Redmile Group
North America, California, United States, San Francisco
Co-Investments: 10

Which angels does Sanofi Ventures often collaborate with?

AI
North America, California, United States, Los Angeles
Shared Deals: 1
GF
North America, California, United States
Shared Deals: 2
HT
Europe, Noord-Brabant, The Netherlands, Tilburg
Shared Deals: 1
PM
North America, Massachusetts, United States, Cambridge
Shared Deals: 1
SH
North America, California, United States, Santa Monica
Shared Deals: 1

What are some of recent deals done by Sanofi Ventures?

Draig Therapeutics

Cardiff, New South Wales, Australia

Draig Therapeutics is a clinical-stage biopharmaceutical startup.

BiotechnologyTherapeutics
Series AJun 18, 2025
Amount Raised: $140,000,000
Splice Bio

Barcelona, Catalonia, Spain

Splice Bio develops gene therapies using its Protein Splicing platform for genetic diseases.

BiotechnologyLife ScienceMedicalPharmaceutical
Series BJun 11, 2025
Amount Raised: $135,000,000
Therini Bio

San Francisco, California, United States

Therini Bio specializes in fibrin-targeting therapies to treat inflammatory neurological and retinal diseases.

BiotechnologyHealth CareMedicalTherapeutics
Series AMay 14, 2025
Amount Raised: $39,000,000
Granite Bio

Basel, Basel-Stadt, Switzerland

Granite Bio is a biotechnology business developing novel antibodies to treat inflammatory, autoimmune, and fibrotic disorders.

BiotechnologyTherapeutics
Series BApr 24, 2025
Amount Raised: $70,000,000
Glycomine

San Francisco, California, United States

Glycomine is an early-stage biotech working on replacement therapies for rare diseases.

BiotechnologyPharmaceuticalTherapeutics
Series CApr 16, 2025
Amount Raised: $115,000,000
Attovia Therapeutics

San Carlos, California, United States

Attovia Therapeutics is a biologics platform specializing in biotherapeutics for immune-mediated diseases.

BiotechnologyHealth CareMedicalTherapeutics
Series CApr 15, 2025
Amount Raised: $90,000,000
Curevo

Bothell, Washington, United States

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.

BiopharmaBiotechnologyHealth CareMedical
Series BMar 17, 2025
Amount Raised: $110,000,000
Latigo Biotherapeutics

Thousand Oaks, California, United States

Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain.

BiotechnologyHealth CareMedicalTherapeutics
Series BMar 17, 2025
Amount Raised: $150,000,000
Abcuro

Newton, Massachusetts, United States

Abcuro develops immunotherapies to treat autoimmunity and cancer.

BiotechnologyHealth CareMedicalTherapeutics
Series CFeb 12, 2025
Amount Raised: $200,000,000
AdvanCell

Sydney, New South Wales, Australia

AdvanCell is a clinical-stage radiopharmaceutical company that develops novel cancer therapeutics.

BiotechnologyClinical TrialsOncologyPharmaceutical
Series CFeb 3, 2025
Amount Raised: $112,000,000